Supportive Care | Specialty

The OncLive Supportive Care condition center page is a comprehensive resource for clinical news and expert insights on supportive care and management of patients with cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, best practices, and ongoing research as it relates to supportive care for patients with cancer.

Frontline Therapy Approaches for Small Cell Lung Cancer

December 17th 2019

First-line Immunotherapy: IMPower133 Regimen

December 17th 2019

Immunotherapy Toxicity Profile

December 17th 2019

Negative I/O Trials: CheckMate331 and CheckMate 451

December 17th 2019

Checkpoint Inhibitors in Second and Third-line

December 17th 2019

SCLC Therapy: First-line Options Prior to Immunotherapy

December 17th 2019

The Initial Approach to SCLC Treatment

December 17th 2019

Small Cell Lung Cancer: Future Directions in Care

December 17th 2019

I-O Strategies in Relapsed/Refractory SCLC

December 17th 2019

Frontline I-O Strategies in SCLC: Practical Implications

December 17th 2019

Results From the CASPIAN Trial in SCLC

December 17th 2019

Small Cell Lung Cancer: Interpreting Data From IMpower133

December 17th 2019

Current Frontline Management of Small Cell Lung Cancer

December 17th 2019

Fitness Apps Could Help Cancer Survivors Become More Active

December 6th 2019

About 20% of fitness apps reviewed in a recent study were deemed appropriate for survivors of cancer, showing that they could be an effective tool in helping this population increase physical activity.

ASCO Guidelines on VTE Add New Oral Agents

November 19th 2019

Updated venous thromboembolism (VTE) guidelines issued by the American Society of Clinical Oncology now include the use of direct oral anticoagulants for patients with cancer as a preventive measure against VTE recurrence.

FDA Approves Single-Dose Aprepitant Regimen for MEC

October 22nd 2019

The FDA has expanded the approval of aprepitant (Cinvanti) injectable emulsion for intravenous use to include the 130-mg single-dose regimen for patients receiving moderately epigenetic chemotherapy.

Future of PI3K Inhibition in FL and CLL

September 13th 2019

PI3K Inhibitors in Management of R/R Follicular Lymphoma

September 13th 2019

PI3K Inhibitors in Management of CLL

September 13th 2019

Common Toxicities With PI3K Inhibition

September 13th 2019